← Back to patent-cliff list
Sodium zirconium cyclosilicate
Tier C — Watch / tradeSodium zirconium cyclosilicate
Zs Pharma Inc
Originator
2018
First approval
-
Expiry (public)
$0.7B ▲
Peak sales
Small molecule
Type
Targets：Potassium
Brand：Ziconite, Lokelma, Zircon
Indications (approved)：Hyperkalaemia
Regional status
US
Approved
2018-05-18
EU
Approved
2018-03-22
China
Approved
2019-12-30
Japan
Approved
2020-03-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sodium zirconium cyclosilicate?
Approved indications include: Hyperkalaemia.
When does the Sodium zirconium cyclosilicate patent expire?
No public expiry year is available for Sodium zirconium cyclosilicate yet; this page updates once verified.
How do I get a quote for Sodium zirconium cyclosilicate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29